Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 8 of 13.
Jan 2017
11 Jan · Meeting
11 Jan · Meeting
11 Jan · Meeting
9 Jan · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 09-Jan-2017, informing that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under section 42 and 62 of the Companies Act, 2013 and other necessary approvals. It was further decided that the Company would notify through the newspapers the price of each equity share to be issued in lieu of Warrants calculated in accordance with Regulation 76(1) of Chapter of the SEBI ICDR Regulations on the basis of the Relevant Date for the benefit of the Members."On basis of above the Company is required to clarify following:1. Names of the investors;The response of the Company is awaited.5 Jan · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 05-Jan-2017, regarding "Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.On basis of above the Company is required to clarify following:1. Reasons for cancellation of the same.The response of the Company is awaited.
Dec 2016
Nov 2016
29 Nov · Updates
18 Nov · Limited Review Report
17 Nov · Limited Review Report for September 30, 2016
12 Nov · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 11-Nov-2016, regarding "Bafna Pharmaceuticals Limited has informed the Exchange the Outcome of Board Meeting held on 11th November, 2016".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);The response of the Company is awaited.11 Nov · Board meeting
Oct 2016
20 Oct · Shareholding for the Period Ended September 30, 2016
Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click ....18 Oct · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Sep 2016
30 Sep · Regulation 44(3) of SEBI (LODR), Reg., 2015
Aug 2016
16 Aug · Limited Review Report for June 30, 2016
4 Aug · Meeting
2 Aug · Meeting
Jul 2016
7 Jul · Shareholding for the Period Ended June 30, 2016
Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click ....7 Jul · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) ....1 Jul · Meeting
Jun 2016
22 Jun · Declaration regarding Audit Report with unmodified opinion
22 Jun · Declaration for audit reports with unmodified opinion(s)